• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Spago Nanomedical

0.12 SEK

+4.55 %

Less than 1K followers

SPAGO

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+4.55 %
-10.98 %
-1.05 %
-1.05 %
+16.45 %
-24.67 %
-75.66 %
-97.61 %
-98.57 %

Spago Nanomedical is active in biotechnology. The company develops nanomedicine for the diagnosis and treatment of life-threatening diseases. The company's main activities are focused on developing a cancer-selective contrast agent for magnetic resonance imaging (MRI), as well as a product for radionuclide treatment of cancer. Both of these projects are based on proprietary nanomaterials. The largest operations are in the Nordic market, with the headquarters located in Lund.

Read more
Market cap
92.99M SEK
Turnover
31.17K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
20.8.
2026

Interim report Q2'26

5.11.
2026

Interim report Q3'26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release5 hours ago

DNB Carnegie Access: Spago Nanomedical – Ett viktigt steg framåt

Spago Nanomedical
Regulatory press releaseyesterday

Bulletin from the 2026 Annual General Meeting of Spago Nanomedical AB

Spago Nanomedical
Press release6/3/2026, 6:00 AM

The subscription period in Spago Nanomedical’s rights issue begins today

Spago Nanomedical

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release6/2/2026, 6:00 AM

Spago Nanomedical publishes information document in connection with forthcoming rights issue

Spago Nanomedical
Press release5/22/2026, 2:33 PM

DNB Carnegie Access: Spago Nanomedical: Raises capital

Spago Nanomedical
Regulatory press release5/22/2026, 6:03 AM

Spago Nanomedical resolves on a rights issue of approximately SEK 16 million

Spago Nanomedical
Press release5/19/2026, 6:55 AM

Spago Nanomedical publishes the annual report for 2025

Spago Nanomedical
Press release5/18/2026, 6:00 AM

Spago Nanomedical presents Tumorad® clinical data at the international ANZSNM 2026 conference

Spago Nanomedical
Press release5/12/2026, 8:00 AM

DNB Carnegie Access: Spago Nanomedical - Betydande framsteg i Tumorad-projektet

Spago Nanomedical
Regulatory press release5/11/2026, 8:35 AM

NOTICE TO ANNUAL GENERAL MEETING OF SPAGO NANOMEDICAL AB (PUBL)

Spago Nanomedical
Press release5/8/2026, 8:10 AM

BioStock: Spago Nanomedical reaches primary endpoint in Tumorad-01

Spago Nanomedical
Press release5/8/2026, 6:07 AM

DNB Carnegie Access: Spago Nanomedical: Making steady progress – Q1 review

Spago Nanomedical
Regulatory press release5/7/2026, 6:00 AM

Spago Nanomedical interim report January-March 2026

Spago Nanomedical
Press release5/6/2026, 11:18 AM

DNB Carnegie Access: Spago Nanomedical: MTD identified, promising signs of tumour uptake

Spago Nanomedical
Press release5/6/2026, 8:51 AM

Spago Nanomedical's phase I/IIa study Tumorad-01 meets a primary endpoint and provides further visible tumor uptake

Spago Nanomedical
Press release3/24/2026, 7:00 AM

Spago Nanomedical’s abstract on Tumorad® accepted for presentation at radiopharma conference

Spago Nanomedical
Press release3/17/2026, 1:52 PM

DNB Carnegie Access: Spago Nanomedical: Recruitment expansion greenlit

Spago Nanomedical
Press release3/17/2026, 10:53 AM

Spago Nanomedical continues recruitment in the phase I/IIa Tumorad-01 study following positive DMC recommendation

Spago Nanomedical
Press release3/10/2026, 7:00 AM

Spago Nanomedical strengthens CMC and supply capabilities to support next phase of Tumorad development

Spago Nanomedical
Press release2/6/2026, 1:20 PM

DNB Carnegie Access: Spago Nanomedical: Nearing the next DMC decision – Q4 review

Spago Nanomedical